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In Brief
Statin-induced myopathies are the most
common side effects of thesewidely used
cholesterol-lowering drugs, affecting
millions of patients. Schirris et al.
identified the Qo site of mitochondrial
complex III as off-target of statin lactones
and show possible mechanisms for the
attenuation of their inhibitory effect.
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Cholesterol-lowering statins effectively reduce the
risk of major cardiovascular events. Myopathy is
the most important adverse effect, but its underlying
mechanism remains enigmatic. In C2C12 myoblasts,
several statin lactones reduced respiratory capacity
and appeared to be strong inhibitors of mitochon-
drial complex III (CIII) activity, up to 84% inhibition.
The lactones were in general three timesmore potent
inducers of cytotoxicity than their corresponding
acid forms. The Qo binding site of CIII was identified
as off-target of the statin lactones. These findings
could be confirmed in muscle tissue of patients
suffering from statin-induced myopathies, in which
CIII enzyme activity was reduced by 18%. Respira-
tory inhibition in C2C12 myoblasts could be attenu-
ated by convergent electron flow into CIII, restoring
respiration up to 89% of control. In conclusion,
CIII inhibition was identified as a potential off-
target mechanism associated with statin-induced
myopathies.
INTRODUCTION
Statins (HMG-CoA reductase inhibitors) are cholesterol-lowering
drugs that are effective in reducing the risk of major cardio-
vascular events. They are among the most commonly pre-
scribed drugs worldwide. Although statins are generally well
tolerated, myopathies are the most frequent adverse effects,
ranging from muscle pain with rates up to 26% to very rare
cases of life-threatening rhabdomyolysis (Alfirevic et al., 2014).
Although statin-induced rhabdomyolysis is uncommon, unac-
ceptably high rates were observed with cerivastatin, leading to
its withdrawal from the market (Armitage, 2007; Furberg and
Pitt, 2001).Cell MeThe risk of developing statin-induced myopathies greatly de-
pends on the type of statin, as illustrated by a recent large-scale
post-marketing study (Hoffman et al., 2012). The differences
could at least partially be explained by their relative potencies
to inhibit cholesterol synthesis, but are also expected to depend
on other effects, such as statin metabolism, drug-drug interac-
tions, statin dose, and lipophilicity (Abd and Jacobson, 2011;
Hoffman et al., 2012). In addition, a number of patient-related
risk factors (age, co-morbidities, gender, genetics, ethnicity)
have been identified (Abd and Jacobson, 2011; Taha et al.,
2014). This led to the association of statin-induced myopathies
with several genetic polymorphisms in various drug transporters,
autophagy clearance pathways, and enzymes involved in crea-
tine synthesis (Mangravite et al., 2013; Needham and Mastaglia,
2014; Link et al., 2008; Zeharia et al., 2008; Zhang et al., 2014).
However, not every affected patient is a carrier of such a poly-
morphism, and additional studies are warranted to determine
their significance (Ballard and Thompson, 2013; Floyd et al.,
2014; Luzum et al., 2015). These insights have led to several
putative mechanisms to explain statin-induced myopathies,
including disturbed calcium homeostasis, decreased protein
prenylation, and increased atrogin-1 expression (Abd and Ja-
cobson, 2011; Hanai et al., 2007).
Another hypothesis suggests a pivotal role for mitochondrial
dysfunction, often ascribed to decreased coenzyme-Q10 synthe-
sis (Marcoff and Thompson, 2007; Sirvent et al., 2008). However,
clinical trials on the effect of coenzyme-Q10 supplementation
gave equivocal results, questioning its pathomechanistic role
in statin-induced myopathy (Parker et al., 2013; Sirvent et al.,
2008).
Further widening the range of possible scenarios, most statins
are administered in their pharmacologically active acid form, but
uridine 50-diphospho-glucuronosyltransferases (UGTs) convert
them into the lactone form (Prueksaritanont et al., 2002). The
highly polymorphic nature of these UGTs may further contribute
to the large inter-individual differences in conversion rates and
ensuing lactone levels, as has been shown for the UGT1A1*28
polymorphism in relation to atorvastatin lactonization (Stormo
et al., 2013).tabolism 22, 399–407, September 1, 2015 ª2015 Elsevier Inc. 399
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Figure 1. Temporal Investigation of Statin-Induced Cytotoxicity and Acute Inhibition of Oxygen Consumption and Mitochondrial ATP
Production
(A) Long-term (24 hr) effects of the statins on cell viability were investigated in parallel for determination of the effects of direct statin exposure on ATP production
and oxygen consumption.
(B) The number of apoptotic (gray) and necrotic (black) C2C12 cells was determined after exposure to the acid (A) or lactone (L) form of eight statins (atorvastatin,
ATOR; cerivastatin, CERI; fluvastatin, FLUV; lovastatin, LOVA; pitavastatin, PITA; pravastatin, PRAV; rosuvastatin, ROSU; and simvastatin, SIMV). The total
number of cytotoxic (apoptotic and necrotic) cells was expressed as percentage of the total number of cells present, followed by determination of the cytotoxicity
EC50 value.
(C) Basal respiratory rates were determined after acute application of the statin acid (black) or lactone (gray) form at their cytotoxic EC50 concentration, or at least
two times (2–8 times) the EC50 value of the corresponding lactone (if EC50 > 300). Data are expressed as percentage of the vehicle (42 ± 2 pmol O2/s/10
6 cells).
(D) Maximal ATP production was measured in permeabilized C2C12 cells after acute exposure to the statin acid (black) or lactone (gray) form at concentrations
described under (C). Data are expressed as percentage of vehicle (29 ± 3 nmol/hr/mU CS). ND: not determined due to precipitation in this particular buffer.
(E–H) Under conditions similar to the ATP production measurements the effects of the acid (black) or lactone (gray) form of the indicated statin on (E) CI-, (F)
CII-, (G) glycerol-3-phosphate dehydrogenase (G3PDH)-, or (H) CIV-driven oxygen consumption were examined. Data are expressed as percentage of
(legend continued on next page)
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Here, we demonstrate a molecular off-target mechanism that
can explain mitochondrial-related myotoxicity by several statins.
RESULTS AND DISCUSSION
Compared to Their Acid Forms, Statin Lactones Are
More Potent in Inducing Cytotoxicity and Reducing
Respiration and Mitochondrial ATP Production
To evaluate the role of statin-inducedmitochondrial dysfunction,
we explored the cytotoxic mechanism in C2C12 myoblasts. This
cell model was chosen because it displays similar cellular
features as those observed during statin-induced myotoxicity
in humans, such as lowered protein prenylation and N-linked
glycosylation levels, unchanged cellular cholesterol and coen-
zyme Q levels, and decreased antrogin-1-mediated Akt phos-
phorylation (Mullen et al., 2010, 2011). Since previous work
indicated that the statin lactones are more potent inducers of
cytotoxicity than their acid counterparts (Skottheim et al.,
2008), both the acid and lactone forms of eight statins were
investigated in this study. In agreement with the above study,
long-term statin exposure (Figure 1A) revealed a higher cytotoxic
potency (EC50) for seven lactones as compared to their acid
counterparts (Figure 1B). Also in terms of cytotoxic efficacy,
the lactone forms of six statins scored significantly higher than
their acid counterparts (Figure 1B). With the exception of lova-
statin lactone, apoptosis appeared to be the major mechanism
of cytotoxicity for both lactones and acids (Figure 1B). To avoid
possible interference of adaptive responses, acute statin expo-
sure was analyzed, which revealed that the lactone forms of
atorvastatin, cerivastatin, and pitavastatin caused an immediate
decrease in the basal oxygen consumption rate of resting cells
(Figure 1C). This observation was in agreement with the previ-
ously reported decrease in CI-driven respiration in statin-treated
volunteers (Sirvent et al., 2012) and indicated a direct inhibitory
effect on the mitochondrial ATP production machinery (Fig-
ure 1C). Corroborating this conclusion, the lactone forms of ator-
vastatin, cerivastatin, and simvastatin proved to be much more
potent than their acid counterparts in acutely decreasing the
maximal rate of mitochondrial ATP production in permeabilized
C2C12 myoblasts (Figure 1D).
Statin Lactones Specifically Inhibit the Enzymatic
Activity of CIII of the Respiratory Chain
To address the possible involvement of individual respiratory
chain complexes in the inhibitory action of statins, we went on
to measure the effect of acids and lactones on the maximal res-
piratory rates in the presence of complex-specific substrates.
Compared to their acid counterparts, the lactones of atorvasta-
tin, cerivastatin, and pitavastatin significantly inhibited maximal
CI-, CII-, and glycerol-3-phosphate dehydrogenase (G3PDH)-
driven respiration (Figures 1E–1G). The latter activity was also
significantly inhibited by the lactones of lovastatin and simva-vehicle-treated control: 125 ± 7 pmol O2/s/10
6 cells for CI, 125 ± 7 pmol O2/s/10
cells for CIV.
Statistical analysis: one-way or two-way ANOVA with Bonferroni post hoc analysi
between apoptotic and necrotic levels (within bars, only B), or to compare diff
**p < 0.01, ***p < 0.001. Mean ± SEM; n = 3 independent experiments.
Cell Mestatin. Intriguingly, the acid form of fluvastatin acid inhibited CI-
and CII-driven respiration; however, it only marginally affected
G3PDH-driven respiration (Figures 1E–1G). Importantly, none
of the statins significantly inhibited CIV-driven respiration (Fig-
ure 1H). Statin exposure did not affect the mitochondrial mem-
brane potential, thus excluding their action as a mitochondrial
uncoupler (data not shown). These results pointed toward a spe-
cific inhibitory effect of several lactone statins on the enzymatic
activity of mitochondrial CIII. Indeed, direct testing of the effects
on the individual enzymatic activities of all five complexes re-
vealed significant inhibition by 5 out of 8 statin lactones only
for complex III (Figures S1A–S1E). For atorvastatin lactone we
noted a much stronger effect on ATP production rate (Figure 1D)
than on the other activities involving complex III (Figures 1E–1G),
which may indicate an additional off-target for this compound.
However, we did not further explore this possibility as it was
beyond the scope of this study.
For a better comparison of the effect of the different statins on
CIII, we measured ubiquinol:cytochrome c oxidoreductase ac-
tivity in broken C2C12 mitochondria after acute statin exposure
at a fixed concentration for all compounds (Figure 2A). As ex-
pected, CIII inhibition by cerivastatin, pitavastatin, lovastatin,
and simvastatin was much more pronounced, whereas also in
this assay fluvastatin acid was without effect. Interestingly, the
lactone that exhibited the strongest inhibition was that of ceri-
vastatin, which was withdrawn from the market because of its
high rhabdomyolysis activity. The inhibitory effect of the lactones
was not mimicked by the acids and seemed to depend, at
least partially, on their lipophilicity, because no inhibition was
observed with lactones with an intermediate (e.g., fluvastatin)
or low (e.g., pravastatin and rosuvastatin) lipophilicity (see also
Abd and Jacobson, 2011; Taha et al., 2014). Finally, we could
confirm reversibility of CIII inhibition by showing recovery of ac-
tivity after washing of a statin-treated mitochondrial fraction
(Figure S1F).
Statin Lactones Inhibit the Qo Site of CIII
Since CIII contains two potential binding sites (Qo andQi) (Brandt
and Trumpower, 1994) for the statin lactones (Figure 2B), we
further explored their inhibitory mechanism of interaction by
in silico off-target predictions with the structure-based pharma-
cophore fingerprint method KRIPO (Wood et al., 2012). An off-
target should have a pocket comparable to the pharmacological
target in order to bind the drug. Therefore, pharmacophore
models of statin (sub-)pockets of HMG-CoA reductase were
constructed (Figure S2A). Next, the sub-binding pockets derived
from these models were compared with a library of more than
300,000 (sub-)binding pockets revealing high similarity to the
sub-binding pockets of the Qo and Qi binding sites of CIII. Both
sites are involved in the transfer of electrons from coenzyme
Q to cytochrome c involving cytochromes c1 and b (Figure 2B).
Docking predicted binding of the statin lactone form (Figure 2C),6 cells for CII, 82 ± 6 pmol O2/s/10
6 cells for G3PDH, 226 ± 10 pmol O2/s/10
6
s, to compare values to vehicle control (on top of bars), to compare differences
erences between acids and lactones (on top of connecting lines) *p < 0.05,
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Figure 2. Mechanism of Statin-Induced Inhibition of CIII
(A) The effects on the enzyme activity of CIII in C2C12 mitochondria of 100 mM of the acid (black) and lactone (gray) forms were determined. The data presented
are expressed as percentage of vehicle-treated control (1,200 ± 160 mU/U CS). See Figure S1 for the effects on the enzyme activity of CI, CII, CIV, and CV.
(B–H) Next, in silico docking was performed to investigate whether the statin acid and lactone forms fit into the Qo or Qi binding pocket of CIII (B). Positions in this
Qo binding pocket were modeled with (C) the lactone (green) and (D) the acid (cyan) form of simvastatin. The lactone ring forms hydrogen bonds (yellow dashes)
with the backbone of Glu-272 (Glu-271 in bovine X-ray structures). See Figure S2 for crystal structures and docking of the statin acid and lactone forms into the Qi
binding pocket of CIII. (B and E–H) Reduction of the CIII cytochromes c1 and b was determined spectrophotometrically in bovine heart mitochondria. Difference
spectrum of a sample fully reduced by the addition of dithionite, showing the absorbance peaks of cytochrome c1 (553 nm, blue) and cytochrome b (562 nm, red)
(representative spectral trace shown in B). Simvastatin lactone or acid was added at the indicated concentration, followed by the addition of 50 mMdecylubiquinol
(DUH2). The difference spectrum obtained was used to calculate the reduction state of (E) cytochrome c1 and (F) cytochrome b. (G and H) Similar to the difference
spectra obtained with the statins, spectra were also recorded with and without known CIII inhibitors (G) myxothiazol (myxo, 100 mM), a Qo site inhibitor, and (H)
antimycin A (AA, 25 mM), a Qi site inhibitor. The values at 553 nm and 562 nm obtained with dithionite were set at 100% towhich the values presented on top of the
spectra were related. For statin abbreviations see Figure 1. Statistical analysis: one-way ANOVA with Bonferroni post hoc analysis, **p < 0.01, ***p < 0.001.
Mean ± SEM; n = 3 independent experiments.but not the acid form (Figure 2D) to the Qo site. Acid binding
is most likely hampered due to repulsive interactions with
Glu-272. This prediction is supported by the previously pub-
lished observation that the ester of crocasin, which resembles
the lactone form of statins, but not the acid form, can bind to
the Qo site of CIII (Crowley et al., 2008).
Docking of statins into the Qi site was also feasible (Figures
S2D and S2E). Therefore, we went on to determine the statin
binding site within CIII experimentally by measuring the effects
of simvastatin, one of the currently most widely used statins, on402 Cell Metabolism 22, 399–407, September 1, 2015 ª2015 Elseviethe ubiquinol-induced reduction of cytochromes c1 and b in iso-
lated heart bovine mitochondria (Brandt et al., 1988) (Figure 2B).
Simvastatin lactone inhibited the reduction of cytochrome c1
(Figure 2E), but not b (Figure 2F). Importantly, this inhibition
pattern resembled that of the bona fide Qo site inhibitor myxo-
thiazol (Figure 2G) characterized by a lowered reduction of
cytochrome c1 but an unaffected reduction of cytochrome b,
which is reduced by reversed electron flow through the Qi
site under these conditions (Brandt et al., 1988). In contrast,
simvastatin lactone did not mimic the pattern of the Qi siter Inc.
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(A–F) Muscle biopsies were obtained, following informed consent, from healthy controls (CT) and patients (PAT) with statin-induced myopathies and were used
for preparation of amitochondrial-enriched fraction. (A–D) Enzyme activities of CI to CIVweremeasured in a snap-frozenmitochondrial fraction and normalized to
citrate synthase (CS) content. (E) ATP production capacity was measured in a freshly prepared mitochondrial fraction and normalized to CS. Statistical analysis:
two-sided Student’s t test withWelch’s correction when variances were significantly different according to F-test, *p < 0.05, **p < 0.01, mean ± SD, n as indicated
in figure. (F) Muscle statin accumulation is expressed as the muscle/plasma concentration ratio. Muscle concentrations (nmol/kg wet weight) were determined in
muscle homogenates of 14 patients in total, using four different statins. Free plasma steady-state concentrations (nmol/l) were calculated from the administered
dose using first-order kinetics. Ratios were 0.82 for pravastatin, 6 ± 2 for rosuvastatin, 300 ± 160 for atorvastatin, and 490 ± 120 for simvastatin. For statin
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different statins is expressed as the logD value. (Distribution coefficients were adapted fromWhite, 2002.) See Tables S1, S2, S4, and S5 for more detailed patient
characteristics and age- and gender-corrected statistical analysis.inhibitor antimycin A characterized by increased cytochrome b
reduction under the conditions applied (Figures 2F and 2H). The
acid form, however, failed to affect the reduction of both cyto-
chromes (Figure 2E). This reduction pattern indicates (Brandt
et al., 1988) that statin lactones act primarily at the Qo site to
exert their inhibitory effect on mitochondrial ATP production.
Mitochondrial CIII Activity Is Decreased in Muscle of
Patients with Statin-Induced Myopathies
To assess the in vivo relevance of our in vitro observations, we
analyzed muscle biopsies from 37 patients with statin-induced
myopathies (for study design see Supplemental Experimental
Procedures and for detailed patient information see Table S1).
This analysis revealed a significant decrease in CIII enzyme
activity (Figures 3A–3D) and mitochondrial ATP productionCell Mecapacity (Figure 3E), of which the former remained statistically
significant after correction for age and gender (Table S2). No
relation was observed with co-medication, BMI, smoking
pattern, or alcohol use (for an overview of these variables, see
Table S1). On the other hand, a significant correlation was
observed between CIII activity and clinical presentation (rs =
0.371, p = 0.024), with patients with proximal muscle weakness
and rhabdomyolysis showing the smallest and largest decrease
in CIII activity, respectively.
Subsequently, we used stored muscle biopsy material of 14
patients who gave additional informed consent to determine
the total amount of statin (acid and lactone). Relative to the
calculated steady-state plasma concentration, a marked accu-
mulation of the lipophilic statins atorvastatin and simvastatin
was observed (Figure 3F), as has been hypothesized previouslytabolism 22, 399–407, September 1, 2015 ª2015 Elsevier Inc. 403
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Figure 4. Opportunities to Attenuate Statin-Induced Inhibition and Identification of Increased Susceptibility to Statin-Induced Cytotoxicity
Associated with Lowered Complex III Activity
(A–D) Attenuation of statin-induced inhibition of the respiratory capacity was investigated by additional reduction of endogenous coenzyme Q, which was ob-
tained by convergent electron flows generated by stimulation of glycerol-3-phosphate dehydrogenase (G3PDH, red) with glycerol-3-phosphate (20 mM) or with
b-oxidation (bO, blue) substrates butyric acid (4 mM) and palmitoyl-l-carnitine (20 mM), simultaneous to the stimulation with either (B) CI-, (C) CII-, or (D) CIV-
respiration substrates (gray). Respiratory rates were determined after direct application of the statin lactone form at their cytotoxic EC50 concentration. For each
condition, the value obtained in the presence of statin was expressed as percentage of the values obtained in the absence of statins (171 ± 8 pmol O2/s/10
6 cells
and 139 ± 8 pmol O2/s/10
6 cells for CI +G3PDH andCI + bO; 160 ± 8 pmol O2/s/10
6 cells and 166 ± 10 pmol O2/s/10
6 cells for CII + G3PDH andCII + bO; and 257 ±
10 pmol O2/s/10
6 cells and 266 ± 10 pmol O2/s/10
6 cells for CIV + G3PDH and CIV + bO).
(E) Primary skin fibroblasts of two healthy controls (C5120, black; C6855, gray) and three CIII-deficient patients (P5847, red; P6147, blue; P6748, green) were
isolated and cultured.
(F) Skin fibroblasts were exposed for 24 hr to the indicated statins at concentrations ranging up to 300 mM.
(legend continued on next page)
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(Skottheim et al., 2008). On the other hand, the more hydrophilic
statins, pravastatin and rosuvastatin, displayed noticeably lower
accumulation values (Figure 3F).
Statin-Induced Respiration Inhibition Is Attenuated by
Reduced Coenzyme Q
Next, we explored strategies to mitigate the off-target effects
of statins. Based on the present finding that lactones act on
the Qo site of CIII to inhibit CI-, CII-, and G3PDH-driven respira-
tion, we investigated the effect of an additional increase of the
endogenous pool of reduced coenzyme Q through concomitant
stimulation of either the G3PDH or b-oxidation pathway (Fig-
ure 4A). Such a concomitant stimulation results in a convergent
electron flow into coenzyme Q (Gnaiger, 2009), as could also
be observed with vehicle-treated C2C12 myoblasts, when com-
paring the combined substrate respiration to the single substrate
respiratory rates (Table S3). The data obtained show a partial
(cerivastatin lactone and pitavastatin lactone) to almost com-
plete (atorvastatin lactone and simvastatin lactone) reversal of
the inhibitory effect of these lactones on CI- and CII-driven oxy-
gen consumption (Figures 4B and 4C). As expected, convergent
electron flow did not alter CIV-driven oxygen consumption (Fig-
ure 4D). This demonstrates that the degree of lactone inhibition
of Qo depends on the ambient reduced coenzyme Q level
competing for the same binding site. Moreover, these results
may shed light on the association between statin-inducedmyop-
athies and carnitine-palmitoyltranferase-2 (CPT2) dysfunction
(DiNicolantonio, 2012; Hur et al., 2014; Vladutiu et al., 2006).
CPT2 is involved in mitochondrial fatty acid uptake, and its defi-
ciency will lead to a decreased availability of fatty acids for
b-oxidation. According to our model, this leads to a decreased
convergent electron flow and, thus, to a reduced ability to
reverse lactone inhibition of CIII. In agreement with this hypoth-
esis, stimulation of fatty acid uptake by supplementation of
L-carnitine was found to ameliorate statin-induced muscle and
liver damage (Arduini et al., 2004). Our present observations
provide an experimental rationale for treatment of patients
with statin-induced myopathies with therapeutics that increase
convergent electron flow.
Statin-Induced Cytotoxicity Is Increased in Primary Skin
Fibroblasts of CIII-Deficient Patients
Next, we addressed the possibility that patients with a defi-
ciency of CIII are at risk of statin-induced myopathies. Statin-
induced cytotoxicity was evaluated in primary human skin
fibroblasts of two healthy controls and three CIII-deficient pa-
tients (Figures 4E and 4F). The emerging picture is that patient
fibroblasts are more sensitive to the lactone forms of cerivas-
tatin, lovastatin, and pitavastatin than the control fibroblasts
(Figure 4G, right panel). On the other hand, no such difference
in sensitivity was observed with any of the acids tested (Fig-
ure 4G, left panel).(G) Cytotoxicity EC50 values were determined as described in Figure 1B. For sta
Statistical analysis was as follows: (B–D) one-way or two-way ANOVA with Bonfer
to compare differences between groups (on top of the connecting lines) *p < 0.05
to compare values either to control C5120 *p < 0.05, ***p < 0.001 or to control
experiments.
Cell MeConclusions
In conclusion, we demonstrate that the Qo site of respiratory CIII
is inhibited by several statin lactones and provide evidence for an
association between this off-target effect and statin-induced
myopathies. Consequently, polymorphisms of UGTs, the en-
zymes converting statin acids into lactones, and CIII could be
predisposing factors in statin-induced myopathies. We showed
that both G3PDH and b-oxidation stimulation can prevent
statin-induced respiratory inhibition, providing a rationale for
therapeutic intervention.EXPERIMENTAL PROCEDURES
Analysis of Cell Death
Twenty-four hours prior to statin treatment, C2C12 myoblasts or primary skin
fibroblasts were seeded in 384-well black/clear imaging plates (Santa Cruz
Biotechnology) and exposed to the indicated statins up to maximum solubility
(300 mM). After 24 hr exposure, nuclei were stained for cell viability and imaged
with a high-throughput microscope. See Supplemental Experimental Proce-
dures for more details.
Analysis of Cellular and Mitochondrial Respiration
For measurement of the cellular respiration rate, 1.5 3 106 C2C12 cells were
resuspended in mitochondrial respiration medium MiR05 and transferred to
the thermostatted (37C) chamber of an Oxygraph-2k equipped with DatLab
5 recording and analysis software (Oroboros Instruments). Mitochondrial
respiration driven by the separate respiratory chain complexes was measured
after digitonin permeabilization (10 mg/1 3 106 cells) of the cell membrane in
MiR05 containing complex-specific substrates and 4 mM ADP (Kuznetsov
et al., 2008). See Supplemental Experimental Procedures for more details
about the specific substrates used.
Mitochondrial ATP Production Capacity
C2C12 cells were resuspended in PBS with 3% BSA (Fisher Scientific), to a
final density of 103 106 cells/ml. Mitochondrial ATP production from pyruvate
was measured in the presence of digitonin (200 mg/1 3 106 cells) in duplicate,
as described previously (Janssen et al., 2006; Renkema et al., 2015). See
Supplemental Experimental Procedures for more details.
Enzyme Activity of Individual OXPHOS Complexes
C2C12 pellets of 20 3 106 cells were snap frozen in liquid nitrogen and kept
at 80C until use. For preparation of the mitochondrial fractions, tissues
and cells were homogenized as described in the Supplemental Experimental
Procedures. In addition, for the CVmeasurements, the 600 g supernatant con-
taining the mitochondria was pelleted at 14,000 g for 10 min, resuspended
in 10 mM Tris-HCl (pH 7.6), and snap frozen in aliquots. Enzyme activity of
OXPHOS complexes was measured spectrophotometrically in duplicate in
the absence and presence of the different statins, as described previously
(Janssen et al., 2007; Mourmans et al., 1997; Rodenburg, 2011). See Supple-
mental Experimental Procedures for more details.
Complex III Cytochromes Reduction
The ubiquinol-induced reduction of CIII cytochromes c1 and b was measured
in a preparation of isolated heart bovine mitochondria (Brandt et al., 1988)
using the end-on photomultiplier setup of a Lambda 18 UV-Vis spectro-
photometer (Perkin Elmer). See Supplemental Experimental Procedures for
more details.tin abbreviations see Figure 1.
roni post hoc analysis, to compare values to vehicle controls (on top of bars) or
, **p < 0.01, ***p < 0.001; (G) one-way ANOVA with Dunnett’s post hoc analysis
C6855 #p < 0.05, ##p < 0.01, ###p < 0.001. Mean ± SEM; n = 3 independent
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In Silico Off-Target Prediction
The structure-based pharmacophore fingerprint method KRIPO (Wood et al.,
2012) was used to detect (partial) similarities between HMG-CoA reductase
and protein structures present in the RCSB Protein Data Bank (Berman
et al., 2000) (http://www.rcsb.org) in order to find new statin off-targets (e.g.,
targets other than the pharmaceutical target that underlie the toxic effects).
First, pharmacophore representations of the HMG-CoA reductase statin
(sub-)pockets were generated and were compared to all protein (sub-)pocket
entries of the PDB (March 2013). See Supplemental Experimental Procedures
for more details.
Docking of Statins
To explore possible bindingmodes between statins and CIII, both the acid and
lactone forms were docked into the Qo and Qi binding pockets of CIII. Docking
was performed using Molecular Operating Environment (MOE) software
2012.10 (Chemical Computing Group, Inc.) following the rigid receptor proto-
col. For the docking, an X-ray structure of CIII was selected, in which the Qo
binding site is occupied by a iodinated analog of the polypetide crocacin-D
and the Qi site by coenzyme Q (PDB: 3CWB) (Crowley et al., 2008) (Figures
S2B and S2C).
Patient Muscle Biopsies
Thirty-seven patients with statin-induced myopathy were retrospectively
selected (2008–2013) from a cohort of 1,386 patients from whom a muscle
biopsy (m. quadriceps femoris) was taken after consulting our center with
muscle symptoms. The study was carried out in the Netherlands in accor-
dance with the applicable rules concerning the review of research ethics com-
mittees (Commissie MensgebondenOnderzoek Regio Arnhem-Nijmegen) and
informed consent. Results obtained for diagnostic purposes were anonymized
before use. See Supplemental Experimental Procedures for more details
about the study design.
Determination and Calculation of Muscle and Plasma Statin
Concentrations
Muscle tissue homogenates of 14 patients with statin-induced myopathies
were used. Statin concentrations were determined using liquid chromatog-
raphy-tandemmass spectrometry. Free plasma statin steady-state concentra-
tions of individual patients were estimated using first-order pharmacokinetic
equations. See Supplemental Experimental Procedures for more details on
parameters used for these calculations.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and five tables and can be found with this article online at http://
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